Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
271.19
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Why Shares of BridgeBio Pharma Skyrocketed This Week
July 21, 2023
The biotech company saw strong results in a phase 3 trial.
Via
The Motley Fool
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
July 20, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
July 19, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings for Alnylam Pharmaceuticals
June 22, 2023
Via
Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
June 21, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
June 16, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
May 31, 2023
Via
Benzinga
Why Alnylam Pharmaceuticals Topped the Market Today
July 17, 2023
Monday was a good day for biotechs fighting the good fight against a common degenerative brain disorder.
Via
The Motley Fool
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 17, 2023
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...
Via
Benzinga
Alnylam Says Single Injection Of RNAi Therapy Cuts Alzheimer's-Linked Proteins By 65%, Stock Soars
July 17, 2023
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced updated interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP for Alzheimer's disease and
Via
Benzinga
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
May 10, 2023
Via
Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,600 Today
May 05, 2023
Via
Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
May 05, 2023
Via
Benzinga
Alnylam Clocks ~50% Revenue Growth In Q1 On Solid Commercial Execution
May 04, 2023
Via
Benzinga
BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease
July 17, 2023
The companies are working on treatments for a leading cause of heart failure.
Via
Investor's Business Daily
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
July 17, 2023
From
Alnylam Pharmaceuticals
Via
Business Wire
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
July 14, 2023
Via
Benzinga
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
June 30, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
June 17, 2023
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
June 09, 2023
Via
Benzinga
Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech
June 07, 2023
Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by
Via
Benzinga
Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Analyst Says Alnylam's New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of Interest
May 22, 2023
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) released new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, for...
Via
Benzinga
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
May 20, 2023
From
Alnylam
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
May 05, 2023
Via
Benzinga
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
May 04, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
May 03, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Issues 2022 Corporate Responsibility Report
May 03, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says
April 27, 2023
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN)
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.